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Nasopharyngeal carcinoma (NPC) is one of head and neck cancer. It has a 
complicated etiology involving Epstein–Barr virus (EBV) infection, environment 
changes, and genetic susceptibility. Early symptoms of NPC are unspecific, so 
most NPC patients are diagnosed at a late stage. An effective population screening 
strategy could increase the early detection and early diagnosis rate. As far, 
serological detection of EBV antibodies such as VCA-IgA, EA-IgA, and EBNA1-IgA, 
are widely used in NPC mass screening; EBV DNA load detection in plasma or 
nasopharyngeal swab was applied to screen in endemic populations for assessing 
the feasibility. However, the current screening schemes still have disadvantages 
such as lowly positive predictive value, unclear effectiveness of screening and 
cost-effectiveness. In the present chapter, we try to review the different screening 
strategies for NPC to understand the future direction of development.
Keywords: Nasopharyngeal carcinoma, Screening, Early diagnosis, Biomarker, 
Epstein–Barr virus, Antibody, DNA load
1. Introduction
Screening is primary measure of secondary prevention of cancer. It mainly 
regularly monitor the asymptomatic high-risk population to achieve the purpose 
of early detection and early treatment of malignant tumors. Cancer carring out the 
secondary prevention should have the following conditions: 1) great harm to the 
health and life of the population; 2) long enough pre-clinical period; 3) better effect 
of both the early treatment and intervention of precancerous lesions; 4) screening 
methods with effective sensitivity and specificity.
Nasopharyngeal carcinoma (NPC) is a one of head and neck cancer. At present, 
the etiology of NPC has not remained completely elucidated, generally considered 
involving Epstein–Barr virus (EBV) infection, environment changes, and genetic 
susceptibility. There are no feasible preventive measures for NPC. However, it 
has secondary prevention. First, NPC exhibiting marked racial and geographical 
differences, is epidemic in the population of Southern China, Southeast Asia, and 
North Africa, which is extremely harmful to human life and health [1]. In 2014, 
the incidence and mortality of NPC were 2.48 per 100,000 and 1.23 per 100,000 in 
China respectively [2]. At the same time, the morbidity and mortality of males were 
higher than females. The morbidity was mainly in the young while the mortality 
was mainly in middle and old age. Besides, the occurrence and development of 
NPC is a multi-stage process, which includes initiation, promotion, malignant 
transformation, and advanced stage of disease [3]. It takes a certain amount of 
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time to develop into a malignant tumor. In addition, the clinical stage of NPC is an 
important factor affecting therapeutic outcome. The 10-year survival rate for NPC 
with stages I and II can reach up to over 90%, whereas for patients with stage III 
and IV is less than 50% [4]. At last, there are effective methods to detect pre-clinical 
patients, and the level of antibody against EBV antigens is significantly related to 
the risk of NPC [5, 6].
NPC first occurs in the epithelium of the nasopharynx, which can invade 
the base of the skull and metastasize to the cervical lymph nodes. It has the 
characteristics of complex manifestations, hidden onset, non-specificity of 
the initial symptoms, and difficulty in early diagnosis. According to statistics, 
patients with NPC at an early stage who came to the hospital accounted for only 
about 20% of the total [7]. Strengthening secondary prevention - early detection, 
early diagnosis, and early treatment - is an important part of the prevention and 
treatment of NPC. At the same time it is the key to improve the cure rate and obtain 
a better prognosis of NPC patients.
2. EBV specific antibodies-based serologic testing
EBV belonging to γ-herpesvirus is a human herpesvirus with B lymphocytes. 
Nearly 95% of adults worldwide are infected with this virus. EBV in infected cells 
can be divided into two states: EBV latent infection and EBV lytic infection. Only 
a few virus genes are expressed in EBV latent infection, which can ensure the basic 
replication function of the virus but lossing infection ability. In EBV lytic infection, 
EBV needs to be activated about 80 ~ 100 viral genes to complete host-to-host 
propagation, and finally produce and form infectious virions (or viral particles). 
After the initial infection, EBV can establish a lifelong latent infection in the host, 
and persistent EBV lysis replication state infection can lead to a series of human 
malignant tumors [8].
EBV infection is closely related to the occurrence and development of NPC. EBV 
latent infection of nasopharyngeal epithelial cells is considered to be a key step in 
the carcinogenesis of epithelial cells. After EBV infection, the expressed virus genes 
can produce different antigens, such as EBV nuclear antigen (EBNA), membrane 
antigen (MA), early antigen (EA), viral capsid antigen (VCA), BZLF1 transcription 
activator protein (Zta), BRLF1 transcription activator protein (Rta), etc. [9].
The detection of antibodies against EBV antigens in the sera of NPC patients 
was reported as early as 1966. Helen W et al. first proposed the view that immuno-
globulin A (IgA) antibodies against EBV can be used for the diagnosis of NPC [10]. 
Studies also confirmed that the expression of IgA antibodies against VCA (VCA-
IgA) in NPC patients was higher than in healthy people and the antibody titer was 
related to the stage of NPC. The idea of using this antibody for NPC screening also 
was proposed [11]. In 1977, Y Zeng et al. established a prospective prevention and 
treatment site for NPC in Cangwu, Guangxi province China, in order to carry out 
research on early diagnosis and etiology analysis. The first NPC mass screening was 
carried out in Cangwu County by the application of the immunoenzymatic (IE) 
method to detect VCA-IgA and EA-IgA [12]. Therefore, the NPC screening model 
suitable for the population in the high-risk areas was established by Zeng’s team. 
Then this mass screening model was promoted to three high-risk areas in China, 
including Guangxi, Guangdong, and Hainan province; and more than four hundred 
thousand people were screened for NPC [13–16]. In the 1980s, similar methods were 
used to screen and follow up large populations in Guangdong and Taiwan provinces 
[17, 18]. SM Cao et al. performed a prospective screening study of 18,986 subjects 
with a 20-year follow-up in Guangdong province using the same method [6]. 
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This study showed that both VCA-IgA and EA-IgA antibodies were effective serum 
markers for NPC screening in high-risk areas. Thus, this method was considered 
as the standard tool for NPC mass screening in China. However, the IE method for 
detecting EBV antibodies also has disadvantages, such as tedious operation, long 
time consuming, no quality control standard, and subjective influence on manual 
interpretation results. These characteristics made it difficult to consistently perform 
in a large population.
Enzyme-linked immunoassay (ELISA) with many advantages compared with 
the IE method, such as simple operation, automatic detection, and interpretation 
of results by a microplate reader, which have subsequently been applied in NPC 
screening. Many studies about using ELISA for NPC screening were reported. The 
detection of ZEBRA-IgG by ELISA was applied to screen NPC, but it’s specificity 
and sensitivity were lower compared with the detection of VCA-IgA based on IE 
[19]. ELISA-based detection of EBV-related antibodies, such as VCA-IgA, EBNA1-
IgA have also found to be a marker for NPC screening [20–22]. The detection rate of 
one single marker was found to be not ideal, and issues such as the combination of 
indicators for joint detection, the setting of thresholds, and the strategy of screen-
ing intervals were discussed.
In Indonesia, the two-step approach employed the EBV IgA ELISA based on 
a combination of VCA p18- and EBNA1-derived synthetic peptides as an initial 
screening test and the EA-IgA ELISA as a confirmation test. The sensitivity and 
specificity for diagnosing NPC using it significantly increased, as well as positive 
predictive value and negative predictive value [23].
JY Guo et al. evaluated the diagnostic effect of VCA-IgA, EA-IgA and Rta-IgG 
antibody detection alone or Combiningly in NPC. The triple-positive of VCA-IgA, 
EA-IgA and Rta-IgG antibodies suggested the highest risk of NPC, and the triple-
negative of them showed the lowest risk [24].
In Taiwan, the ability of anti-EBV-IgA antibody to detect NPC in a high-risk 
population was evaluated. These markers targeted at the following EBV peptides 
including EBNA1, VCAp18, EAp138, Ead_p47 and VCAp18 + EBNA1 peptide 
mixture. The result showed that EBNA1-IgA was a sensitive biomarker for 
differential diagnosis of NPC. At the same time they identified 80% of the high-
risk individuals who developed to NPC during follow-up (80% sensitivity) during 
measuring at baseline [25].
SM Cao’s team developed a prediction formula to calculate Logit P-value 
with VCA-IgA and EBNA1-IgA as variables (Logit P = −3.934 + 2.203 × VCA/
IgA + 4.797 × EBNA1/IgA). The specificity of the new screening scheme is 
equivalent to traditional screening scheme with the IE method (estimated at 
98.5%), but the sensitivity of former (75.0%) is significantly higher than the 
latter (25.0%) [26]. A total of 28,688 Guangdong residents aged 30–59 years were 
screened by the combination of two EBV antibodies tests in addition to indirect 
mirror examination in the nasopharynx and/or lymphatic palpation (IMLP) in 
Sihui and Zhongshan, Guangdong province China. After one year of follow-up, 
the total detection rate of NPC was 0.14% (41/28,688), and the early diagnosis 
rate was as high as 68.3% (28/41) [27]. After six-year follow-up, the sensitivity of 
the new scheme was 95.7%, with AUC = 0.926 (95% CI: 0.885–0.966). The new 
screening scheme for NPC is verified to be the preferred serum diagnostic strategy 
for long-term screening in high-incidence areas of NPC [28]. For the best interval, 
studies have shown that the incidence of NPC was low in the first few years after 
the negative screening and then it would increase to the general population level. 
Therefore, the screening interval of 4–5 years may be more appropriate than 
9–10 years after VCA-IgA negative detection in NPC screening [29]. The above 
research results were adopted by the Chinese Technical Program of Cancer Early 
Pharynx - Diagnosis and Treatment
4
Diagnosis and Early Treatment --Technical Scheme of NPC Screening to guide the 
annual routine population screening in NPC high-risk areas (Figure 1).
However, there are still limitations in NPC screening using EBV antibodies as 
tumor markers. The false-positive rate of EBV serological screening is relatively 
high. The positive rate of EBV antibody in the high-risk areas of NPC is 3% ~ 10%. 
High-risk groups require further examinations, such as nasopharyngeal fibroscopy 
Figure 1. 
Flowchart of NPC screening procedure for nasopharyngeal carcinoma (NPC). EBV, Epstein–Barr virus; ab, 
antibody. Cited by expert group of NPC screening project, expert committee on early diagnosis and treatment 
of cancer project, China. The technical scheme of NPC screening, early diagnosis and early treatment (2015 
edition).
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and nasopharyngeal tissue biopsy. Pathologically diagnosed NPC only accounts for 
1.5% ~ 3.3% of the high-risk population at the initial screening, which further leads 
to a higher false positive rate [27, 30, 31].
3. EBV DNA load detection in plasma or nasopharyngeal swab/brushing
Plasma EBV DNA load detected with polymerase chain reaction (PCR) has been 
also explored to detect early-stage NPC in asymptomatic patients. Research has 
demonstrated that EBV DNA could be quantitatively measured in the blood of NPC 
patients by PCR [32]. A study of 175 patients in New York City found that EBV DNA 
test had much higher specificity and positive predictive value than IgA test alone 
[33]. A systematic review reported that the EBV DNA load test had the largest area 
of 0.932 under the summary receiver operator curve with high sensitivity (73%) 
and specificity (89%), which suggested that EBV DNA detection in plasma could be 
an efficient marker in NPC screening [34].
In Hong Kong, a prospective study of 20,174 participants revealed that EBV 
DNA load in plasma samples was particularly useful in screening for early 
asymptomatic NPC [35]. The participants were ethnically Chinese men at 40 to 
60 years of age. The subjects with initial positive results were detected again after 
about four weeks, while the subjects with persistent positive EBV DNA in plasma 
were performed to check by nasal endoscopy and magnetic resonance imaging 
(MRI). The median duration of follow-up was 22 months (range, 12 to 44 months). 
This study showed that the sensitivity and specificity of this method in NPC 
screening were 97.1% and 98.6% respectively.
However, a study reported that EBV DNA load had a little poor sensitivity and 
specificity for NPC screening among high-risk family members compared with 
EBV-IgA serology [36].
The patients with early NPC may only release a limited amount of viral DNA to 
the blood, making it impossible to detect blood circulation. The potential value of 
plasma EBV DNA detection in screening for early NPC remains controversial. NPC 
mainly originates from epithelial cells in the nasopharynx fossa or posterior wall 
of the nasopharynx. EBV genome can be detected in almost all tumor cells of NPC 
cases [37]. Clonal EBV genome can be continuously detected in invasive cancer and 
precancerous high-grade dysplasia [38]. It is suggested that direct detection of EBV 
genome from nasopharyngeal brushing or swab specimens had highly predictive 
value for screening asymptomatic NPC.
In the 1990s, a prospective study was designed to assess the feasibility of a new 
method for NPC screening by using of PCR coupled with nasopharyngeal swab 
[39]. In this study, 55 patients were enrolled. The result showed that this method 
had a similar sensitivity to serological methods, indicating this new method was a 
good supplement to NPC screening. Nasopharyngeal swab is a quite simple proce-
dure with little discomfort. SP Hao et al. detected the expression of EBV-derived 
latent membrane protein 1 (LMP-1) by nasopharyngeal swab, and he found that 
this strategy could serve as part of a screening program for high-risk populations 
with a sensitivity of 87.3% and a specificity of 98.4% [40]. Raymond’s study has also 
confirmed the effectiveness of this new method of screening for NPC. This study 
performed on 578 patients yielded a sensitivity of 98.9% and a specificity of 99.3% 
with a positive predictive value of 96.9% and a negative predictive value of 99.7% 
[41]. In a prospective and population-based study, the detection of EBV load in the 
nasopharynx by nasopharyngeal swab was demonstrated to be a useful tool as a 
supplement to serological tests [42]. Studies of both Zheng and Zhang also verified 
the same conclusion [43, 44]. Notably, Nasopharyngeal swab detection of EBV load 
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alone should not be used as a mean of NPC screening because of its high false-
positive rate [42]. However, nasopharyngeal swab serving as an applicable sampling 
method for NPC screening is great feasible, but more research will be needed in 
the future.
4. Novel biomarkers/technology for NPC screening
As mentioned above, EBV-related test has been widely used for early NPC 
screening, especially the combination of EBV-antibody VCA-IgA and EBNA1-IgA. 
With the development of research technologies, other biomarkers also develope for 
NPC screening. Liu et al. reported that a combination of PCR and MWCNT-Fe3O4 
nanocomposites had the higher detection rate and higher sensitivity compared 
with the traditional ELISA method [45]. MWCNT-Fe3O4 nanocomposites are 
a combination of multi-walled carbon nanotubes and iron oxide nanoparticles, 
which can provide a large surface areas for antigen–antibody binding. A nested 
case–control study including 20 patients with NPC and 88 normal control showed 
that EBV microRNA BART2-5p had been proved to be a valuable biomarker for 
NPC screening with a sensitivity of 90.9% [46]. Thirteen genes including DNAAF1, 
PARPBP, TTC18, GSTA3, RCN1, MUC5AC, POU2AF1, FAM83B, SLC22A16, SPEF2, 
ERICH3, CCDC81, and IL33 have been associated with NPC detection based on 
comprehensive bioinformatics analyses [47]. A recent study showed that higher 
methylation rates of EGFR and ZNF6671 in circulating cell-free DNA (ccfDNA) 
could predict NPC, which was a potential novel molecular marker for NPC 
screening [48]. However, all these researches need more evidence and more data to 
demonstrate their effectiveness in NPC screening.
Many studies have shown that intestinal flora disruption was associated with 
malignant tumors. C. ramosum bacteria that promotes the secretion of 5-HT was 
found to be a strong risk factor for NPC. The establishment of a disease prediction 
model based on C. ramosum might be used for the prediction of disease risk in a 
high-risk population and early non-invasive screening of NPC [49].
Raman spectroscopy combined with multivariate analysis technology has 
been reported to analyze the sera of NPC patients and healthy individuals. 
In NPC samples, the lipid content, phenylalanine, and β-carotene decreased 
while amide III, tyrosine and tryptophan increased. The changes in these 
biomolecular concentrations may be applied for NPC diagnosis [50]. A unmodified 
nanotechnology based on surface-enhanced Raman spectroscopy was used to 
detect the blood circulating DNA; and the diagnostic sensitivity and specificity for 
differentiating the NPC patients from the normal control were 83.3% and 82.5% 
respeactively. Nanotechnology which was sensitive, rapid, and easy-to-use may 
have the potential to become a better method for NPC detection and screening 
based on liquid biopsy [51].
5. Cost-effectiveness of NPC screening
A Markov stimulation model was constructed to evaluate the cost-effectiveness 
of different screening strategies for serological tests in China. In this study, 
NPC detection rate, cost, quality-adjust life, and incremental cost-effectiveness 
ratio were considered. Results showed that strategy (annual screening for EBV-
seropositive subject, triennial screening for seronegative subjects) was the 
economical and practical option [52]. In 2019, a Markov cohort model was also 
reported to use to estimate the screening for NPC with plasma EBV DNA for 
7
Screening of Nasopharyngeal Carcinoma
DOI: http://dx.doi.org/10.5772/intechopen.97398
50-year-old Asian American men in the United States. The study suggested that 
because of its high false-positive results in high-risk regions and its uncertain 
clinical value in non-endemic areas this method wasn’t the most cost-effective, 
despite its specificity and sensitivity were high [53]. Therefore more research will be 
required in the future.
Studies about NPC screening based on EBV-related test have been widely 
reported, but there are few studies on the association between EBV-antibody 
screening and NPC mortality. Recently a study about prospective, cluster-
randomized, controlled trial in southern China for NPC screening was revealed 
that the combination of EBV antibody EBNA1-IgA and VCA-IgA could effectively 
identify the high-risk population and improve diagnosis of NPC in the interim 
analysis. Although the mortality of the screening group was not significantly 
reduced, the specific mortality of NPC in the screening participants was 
significantly reduced [54]. That was the first report which presented a mortality 
reduction by NPC screening. It is expected to further improve the participation rate 
in the future, and finally confirm the effectiveness of NPC screening based on EBV 
detection.
6. Conclusions and future directions
Due to the hidden location of NPC, it is difficult to diagnose early. Strengthening 
the publicity of NPC prevention and control, popularizing basic knowledge of 
it, and making residents cooperate with screening projects will be way helpful to 
improve the accuracy of early diagnosis rate of NPC. At present, the above screen-
ing methods have positive significance, but they also have limitations regrettably. 
How to make better use of their advantages and disadvantages to carry out local 
screening schemes in different regions is worthy to further exploration. And 
developing faster, simpler, higher true-positive rate and lower false-positive rate 
screening methods and more effective treatment were important ways to improve 
the survival rate and life quality of NPC patients.
Currently, there are few reports from randomized controlled trials (RCT) and 
controlled clinical trials (CCT) to determine the efficacy of screening for NPC 
or the cost-effectiveness of a screening strategy. Future studies with long-term 
follow-up need to systematically assess the impact of the screening methods in 
mortality, assess their ability to detect NPC, evaluate the impact on quality of life 
and cost-effectiveness.
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